| Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling. | |
| | |
MedLine Citation:
|
PMID: 7540314 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Long-term use of topical vasoconstrictors for the nose may result in rhinitis medicamentosa, drug addiction and tachyphylaxis. Some authors also believe that the severity of rebound swelling is proportional to the period during which the drug has been used, the frequency of its administration, and the amount of drug given. It has previously been reported that four-week use of the recommended dose of oxymetazoline induces rebound swelling, a sign of rhinitis medicamentosa. To study the effect of an increased amount of vasoconstrictor on rebound swelling and the decongestive effect of the drug, nine healthy subjects were given xylometazoline nasal spray in double the recommended dose (1.0 mg/ml; 0.28 ml in each nostril thrice daily) for 30 days. After 30 days on xylometazoline, the decongestive effect was the same 1 h after drug administration as before starting the medication. Similarly, after 30 days on xylometazoline, the decongestive effect was less 5 h after drug administration than it was 6 h after drug administration at the start of medication (p < 0.005). After 10 days no rebound swelling was recorded, but after 30 days rebound swelling occurred in eight out of nine subjects (p < 0.05). When comparing the results of this trial with the corresponding results of the oxymetazoline study, no further increase in rebound swelling was found. We conclude that long-term use of xylometazoline nasal spray shortens the decongestive response in healthy volunteers. Moreover, double the recommended dose of xylometazoline did not further increase the rebound swelling seen when using the recommended dose of oxymetazoline. |
| | |
Authors:
|
P Graf; J E Juto |
Related Documents
:
|
7770614 - Effects of lorazepam on human contrast sensitivity. 21130164 - Development and characterization of parenteral nanoemulsions containing thalidomide. 19936714 - Are attention lapses related to d-amphetamine liking? 22528504 - Toward global standards for comparator pharmaceutical products: case studies of amoxici... 21303254 - Drug use among prisoners: by any definition, it's a big problem. 559644 - How much heroin maintenance (containment) in britain? |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Rhinology Volume: 33 ISSN: 0300-0729 ISO Abbreviation: Rhinology Publication Date: 1995 Mar |
Date Detail:
|
Created Date: 1995-07-14 Completed Date: 1995-07-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0347242 Medline TA: Rhinology Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 14-7 Citation Subset: IM |
Affiliation:
|
Department of Otorhinolaryngology, Södersjukhuset, Stockholm, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aerosols Female Humans Imidazoles / administration & dosage, adverse effects*, pharmacology Male Nasal Decongestants / administration & dosage, adverse effects*, pharmacology Nasal Mucosa / drug effects Rhinitis / chemically induced* Time Factors Turbinates / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Aerosols; 0/Imidazoles; 0/Nasal Decongestants; 526-36-3/xylometazoline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The airflow resistance profile of healthy nasal cavities.
Next Document: Septal surgery and tubal function: early and late results.